Compendium of Cancer Genome Aberrations

HAEM5:Volunteer Assignments and Opportunities: Difference between revisions

[checked revision][checked revision]
← Older edit
VisualWikitext
No edit summary
No edit summary
 
(35 intermediate revisions by 3 users not shown)
Line 1: Line 1:
----
Ian Welcome!
----
 
 
Welcome!


'''A new version of the Heme/Lymphoid book (5th edition) is in beta form on the WHO website with publication of a final form anticipated in 2024; we're aligning the related CCGA content to the new structure.'''
'''A new version of the Heme/Lymphoid book (5th edition) is in beta form on the WHO website with publication of a final form anticipated in 2024; we're aligning the related CCGA content to the new structure.'''
Line 13: Line 9:


*To volunteer, please '''[[Mailto:CCGA@cancergenomics.org <u>Contact us</u>]]''' with your page of interest.
*To volunteer, please '''[[Mailto:CCGA@cancergenomics.org <u>Contact us</u>]]''' with your page of interest.
*Note - "NEW (No Prior)" in the 4th edition columns means either the disease is a new entity in the 5th edition or the disease was present in the 4th edition without content previously added.-------
*Note - "NEW (No Prior)" in the 4th edition columns means either the disease is a new entity in the 5th edition or the disease was present in the 4th edition without content previously added.


__TOC__
__TOC__
Line 61: Line 57:
|-
|-
|[[HAEM5:Clonal haematopoiesis|Clonal haematopoiesis]]||Disease||Meenakshi Mehrotra
|[[HAEM5:Clonal haematopoiesis|Clonal haematopoiesis]]||Disease||Meenakshi Mehrotra
|4/8/24, email again in 9/29/25
|4/8/24, email again in 9/29/25; Meenakshi confirmed om 9/30/25.
| ||Pending|| ||Fabiola Quintero-Rivera (FQR)|| ||
| ||Pending|| ||Fabiola Quintero-Rivera (FQR)|| ||
|NEW (No Prior)
|NEW (No Prior)
Line 69: Line 65:
|NEW (No Prior)
|NEW (No Prior)
|-
|-
|[[HAEM5:Clonal cytopenias of undetermined significance|Clonal cytopenias of undetermined significance]]||Disease|| || || || || ||FQR|| ||
|[[HAEM5:Clonal cytopenias of undetermined significance|Clonal cytopenias of undetermined significance]]||Disease||Zejuan Li
|10/3/2025
| ||Pending|| ||FQR|| ||
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
Line 91: Line 89:
|
|
|-
|-
|[[HAEM5:Chronic eosinophilic leukaemia|Chronic eosinophilic leukaemia]]||Disease||PENDING
|[[HAEM5:Chronic eosinophilic leukaemia|Chronic eosinophilic leukaemia]]||Disease||Daynna Wolff
| || || || ||FQR|| ||
|10/14/25|| || || ||FQR|| ||
|Chronic Eosinophilic Leukemia, Not Otherwise Specified
|Chronic Eosinophilic Leukemia, Not Otherwise Specified
|Chelsea D. Kramish; Daynna J.Wolff
|Chelsea D. Kramish; Daynna J.Wolff
Line 99: Line 97:
|
|
|-
|-
|[[HAEM5:Polycythaemia vera|Polycythaemia vera]]||Disease||PENDING
|[[HAEM5:Polycythaemia vera|Polycythaemia vera]]||Disease||
| || || || ||FQR|| ||
| || || || ||FQR|| ||
|Polycythemia Vera (PV)
|Polycythemia Vera (PV)
Line 107: Line 105:
|
|
|-
|-
|[[HAEM5:Essential thrombocythaemia|Essential thrombocythaemia]]||Disease||PENDING
|[[HAEM5:Essential thrombocythaemia|Essential thrombocythaemia]]||Disease||Rebecca Smith, PhD, Director, Genetics Associates, Nashville, TN
| || || || ||FQR|| ||
|10/1/25|| ||Pending|| ||FQR|| ||
|Essential Thrombocythemia (ET)
|Essential Thrombocythemia (ET)
|Rebecca Smith, PhD, Director, Genetics Associates, Nashville, TN
|Rebecca Smith, PhD, Director, Genetics Associates, Nashville, TN
Line 283: Line 281:
|
|
|-
|-
|[[HAEM5:Myelodysplastic/myeloproliferative neoplasm, NOS|Myelodysplastic/myeloproliferative neoplasm, NOS]]||Disease||PENDING
|[[HAEM5:Myelodysplastic/myeloproliferative neoplasm, NOS|Myelodysplastic/myeloproliferative neoplasm, NOS]]||Disease||
| || || || ||FQR|| ||
| || || || ||FQR|| ||
|Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN), Unclassifiable
|Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN), Unclassifiable
Line 1,033: Line 1,031:
|
|
|Check reference format
|Check reference format
|-
!Disease (5th Edition)
!Page Type
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses)
!Date Assigned to Author (5th Edition)
!Target Completion Date (5th Edition)
!Content Status (5th Edition)(Pending or Complete)
!Date Completed by Author (5th Edition)
!Associate Editor
!Date of Last Editor Review (5th Edition)
!Notes (5th Edition)
!Correlated Prior Disease Name (4th Edition)
!Correlated Prior Author (4th Edition)
!Prior Content Status (4th Edition)(Pending or Complete)
!Prior Date of Last Editor Review (4th Edition)
!Prior Notes (4th Edition)
|-
|-
|
|
Line 1,096: Line 1,110:
|
|
|Previously within myeloid section under JH/MS editors
|Previously within myeloid section under JH/MS editors
|-
!Disease (5th Edition)
!Page Type
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses)
!Date Assigned to Author (5th Edition)
!Target Completion Date (5th Edition)
!Content Status (5th Edition)(Pending or Complete)
!Date Completed by Author (5th Edition)
!Associate Editor
!Date of Last Editor Review (5th Edition)
!Notes (5th Edition)
!Correlated Prior Disease Name (4th Edition)
!Correlated Prior Author (4th Edition)
!Prior Content Status (4th Edition)(Pending or Complete)
!Prior Date of Last Editor Review (4th Edition)
!Prior Notes (4th Edition)
|-
|-
|[[HAEM5:Langerhans cell histiocytosis|Langerhans cell histiocytosis]]
|[[HAEM5:Langerhans cell histiocytosis|Langerhans cell histiocytosis]]
Line 1,386: Line 1,384:
|01/24/2022. Emailed 5/1/2025, no response
|01/24/2022. Emailed 5/1/2025, no response
|Date completed by author: 01/24/2022
|Date completed by author: 01/24/2022
|-
!Disease (5th Edition)
!Page Type
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses)
!Date Assigned to Author (5th Edition)
!Target Completion Date (5th Edition)
!Content Status (5th Edition)(Pending or Complete)
!Date Completed by Author (5th Edition)
!Associate Editor
!Date of Last Editor Review (5th Edition)
!Notes (5th Edition)
!Correlated Prior Disease Name (4th Edition)
!Correlated Prior Author (4th Edition)
!Prior Content Status (4th Edition)(Pending or Complete)
!Prior Date of Last Editor Review (4th Edition)
!Prior Notes (4th Edition)
|-
|-
|[[HAEM5:B-lymphoblastic leukaemia/lymphoma|B-lymphoblastic leukaemia/lymphoma]]
|[[HAEM5:B-lymphoblastic leukaemia/lymphoma|B-lymphoblastic leukaemia/lymphoma]]
|Disease
|Disease
|
|To be covered in B-ALL, NOS
|
|
|
|
Line 1,405: Line 1,419:
|[[HAEM5:B-lymphoblastic leukaemia/lymphoma with high hyperdiploidy|B-lymphoblastic leukaemia/lymphoma with high hyperdiploidy]]
|[[HAEM5:B-lymphoblastic leukaemia/lymphoma with high hyperdiploidy|B-lymphoblastic leukaemia/lymphoma with high hyperdiploidy]]
|Disease
|Disease
|Miguel Gonzalez Mancera
|Miguel Gonzalez Mancera, MD
|
|
|
|
|
|Complete (pending review by SK)
|
|
|SK
|SK
Line 1,421: Line 1,435:
|[[HAEM5:B-lymphoblastic leukaemia/lymphoma with hypodiploidy|B-lymphoblastic leukaemia/lymphoma with hypodiploidy]]
|[[HAEM5:B-lymphoblastic leukaemia/lymphoma with hypodiploidy|B-lymphoblastic leukaemia/lymphoma with hypodiploidy]]
|Disease
|Disease
|Miguel Gonzalez Mancera
|Miguel Gonzalez Mancera, MD
|
|
|
|
|
|Complete (pending review by SK)
|
|
|SK
|SK
Line 1,437: Line 1,451:
|[[HAEM5:B-lymphoblastic leukaemia/lymphoma with iAMP21|B-lymphoblastic leukaemia/lymphoma with iAMP21]]
|[[HAEM5:B-lymphoblastic leukaemia/lymphoma with iAMP21|B-lymphoblastic leukaemia/lymphoma with iAMP21]]
|Disease
|Disease
|Holli Drendel
|Holli Drendel, PhD
|Nov 11/2025
|
|
|
|Pending
|?Complete? Looks like tables need more editing.
|
|
|SK
|SK
Line 1,451: Line 1,465:
|
|
|-
|-
!Disease (5th Edition)
|[[HAEM5:B-lymphoblastic leukaemia/lymphoma with BCR::ABL1 fusion|B-lymphoblastic leukaemia/lymphoma with BCR::ABL1 fusion]]
!Page Type
|Disease
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses)
|Karin Miller, MD
!Date Assigned to Author (5th Edition)
|10/9/2025
!Target Completion Date (5th Edition)
|12/5/2025
!Content Status (5th Edition)(Pending or Complete)
|
!Date Completed by Author (5th Edition)
|
!Associate Editor
|SK
!Date of Last Editor Review (5th Edition)
|
!Notes (5th Edition)
!Correlated Prior Disease Name (4th Edition)
!Correlated Prior Author (4th Edition)
!Prior Content Status (4th Edition)(Pending or Complete)
!Prior Date of Last Editor Review (4th Edition)
!Prior Notes (4th Edition)
|-
|[[HAEM5:B-lymphoblastic leukaemia/lymphoma with BCR::ABL1 fusion|B-lymphoblastic leukaemia/lymphoma with BCR::ABL1 fusion]]
|Disease
|Miguel Gonzalez Mancera
|
|
|
|
|SK
|
|
|
|B-Lymphoblastic Leukemia/Lymphoma with t(9;22)(q34.1;q11.2); BCR-ABL1
|B-Lymphoblastic Leukemia/Lymphoma with t(9;22)(q34.1;q11.2); BCR-ABL1
Line 1,485: Line 1,483:
|[[HAEM5:B-lymphoblastic leukaemia/lymphoma with BCR::ABL1-like features|B-lymphoblastic leukaemia/lymphoma with BCR::ABL1-like features]]
|[[HAEM5:B-lymphoblastic leukaemia/lymphoma with BCR::ABL1-like features|B-lymphoblastic leukaemia/lymphoma with BCR::ABL1-like features]]
|Disease
|Disease
|Miguel Gonzalez Mancera
|Mark G. Evans, MD
|
|10/1/2025
|
|11/17/2025
|
|Complete (pending review by SK)
|
|11/8/2025
|SK
|SK
|
|Pending
|
|
|B-Lymphoblastic Leukemia/Lymphoma, BCR-ABL1-Like
|B-Lymphoblastic Leukemia/Lymphoma, BCR-ABL1-Like
Line 1,501: Line 1,499:
|[[HAEM5:B lymphoblastic leukaemia/lymphoma with KMT2A rearrangement|B lymphoblastic leukaemia/lymphoma with KMT2A rearrangement]]
|[[HAEM5:B lymphoblastic leukaemia/lymphoma with KMT2A rearrangement|B lymphoblastic leukaemia/lymphoma with KMT2A rearrangement]]
|Disease
|Disease
|Miguel Gonzalez Mancera
|Gokce A. Toruner, MD, PhD
|
|10/9/2025
|
|11/5/2025
|
|Pending
|
|
|SK
|SK
Line 1,517: Line 1,515:
|[[HAEM5:B lymphoblastic leukaemia/lymphoma with ETV6::RUNX1 fusion|B lymphoblastic leukaemia/lymphoma with ETV6::RUNX1 fusion]]
|[[HAEM5:B lymphoblastic leukaemia/lymphoma with ETV6::RUNX1 fusion|B lymphoblastic leukaemia/lymphoma with ETV6::RUNX1 fusion]]
|Disease
|Disease
|Miguel Gonzalez Mancera
|Gokce A. Toruner, MD, PhD
|
|10/8/2025
|
|12/1/2025
|
|Pending
|
|
|SK
|SK
Line 1,533: Line 1,531:
|[[HAEM5:B-lymphoblastic leukaemia/lymphoma with ETV6::RUNX1-like features|B-lymphoblastic leukaemia/lymphoma with ETV6::RUNX1-like features]]
|[[HAEM5:B-lymphoblastic leukaemia/lymphoma with ETV6::RUNX1-like features|B-lymphoblastic leukaemia/lymphoma with ETV6::RUNX1-like features]]
|Disease
|Disease
|Lei Zhang;
|Lei Zhang, PhD
Michelle Fan (trainee)
Michelle Fan (trainee)
|8/8/2024
|10/10/2025
|
|12/22/2025
|Pending
|Pending
|
|
Line 1,550: Line 1,548:
|[[HAEM5:B lymphoblastic leukaemia/lymphoma with TCF3::PBX1 fusion|B lymphoblastic leukaemia/lymphoma with TCF3::PBX1 fusion]]
|[[HAEM5:B lymphoblastic leukaemia/lymphoma with TCF3::PBX1 fusion|B lymphoblastic leukaemia/lymphoma with TCF3::PBX1 fusion]]
|Disease
|Disease
|Miguel Gonzalez Mancera
|Miguel Gonzalez Mancera, MD
|10/1/2025
|
|
|Pending
|
|
|
|SK
|
|SK
|
|
|
|
Line 1,566: Line 1,564:
|[[HAEM5:B lymphoblastic leukaemia/lymphoma with IGH::IL3 fusion|B lymphoblastic leukaemia/lymphoma with IGH::IL3 fusion]]
|[[HAEM5:B lymphoblastic leukaemia/lymphoma with IGH::IL3 fusion|B lymphoblastic leukaemia/lymphoma with IGH::IL3 fusion]]
|Disease
|Disease
|Miguel Gonzalez Mancera
|Miguel Gonzalez Mancera, MD
|
|10/1/2025
|
|
|
|Pending
|
|
|SK
|SK
Line 1,582: Line 1,580:
|[[HAEM5:B lymphoblastic leukaemia/lymphoma with TCF3::HLF fusion|B lymphoblastic leukaemia/lymphoma with TCF3::HLF fusion]]
|[[HAEM5:B lymphoblastic leukaemia/lymphoma with TCF3::HLF fusion|B lymphoblastic leukaemia/lymphoma with TCF3::HLF fusion]]
|Disease
|Disease
|Aiko Otsubo
|Aiko Otsubo, PhD
|6/25/2024
|10/10/2025
|
|11/24/2025
|Complete (pending SK review)
|11/11/2025
|SK
|Pending
|Pending
|
|SK
|
|
|
|NEW (No Prior)
|NEW (No Prior)
Line 1,598: Line 1,596:
|[[HAEM5:B-lymphoblastic leukaemia/lymphoma with other defined genetic alterations|B-lymphoblastic leukaemia/lymphoma with other defined genetic alterations]]
|[[HAEM5:B-lymphoblastic leukaemia/lymphoma with other defined genetic alterations|B-lymphoblastic leukaemia/lymphoma with other defined genetic alterations]]
|Disease
|Disease
|Lei Zhang;
|Lei Zhang, PhD
Michelle Fan (trainee)
|10/10/2025
|8/8/2024
|12/22/2025
|
|Pending
|Pending
|
|
Line 1,614: Line 1,611:
|-
|-
|[[HAEM5:B-lymphoblastic leukaemia/lymphoma, NOS|B-lymphoblastic leukaemia/lymphoma, NOS]]
|[[HAEM5:B-lymphoblastic leukaemia/lymphoma, NOS|B-lymphoblastic leukaemia/lymphoma, NOS]]
|Disease
|Disease  
|Karin Miller, MD
|10/9/2025
|11/24/2025
|Pending
|
|SK
|
|
|
|
Line 1,620: Line 1,623:
|
|
|
|
|SK
|
|
|
|
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|-
!Disease (5th Edition)
!Disease (5th Edition)
Line 1,646: Line 1,643:
|-
|-
|RESOLVE 4th edition ALL-Related NON-WHO entities content
|RESOLVE 4th edition ALL-Related NON-WHO entities content
|B-Lymphoblastic Leukemia/Lymphoma with t(4;14)(q35.2;q32); IGH/DUX4 + B-Lymphoblastic Leukemia/Lymphoma with dic(9;12)(p13;p13); PAX5/ETV6 + B-Lymphoblastic Leukemia/Lymphoma with ZNF384 Rearrangements + B-Lymphoblastic Leukemia/Lymphoma with IKZF1 Deletions + B-Lymphoblastic Leukemia/Lymphoma with TCF3 Rearrangements - Excluding t(1;19) and t(12;19) + B-Lymphoblastic Leukemia/Lymphoma with dic(9;20)(p13;q11)
|B-Lymphoblastic Leukemia/Lymphoma with t(4;14)(q35.2;q32); IGH/DUX4
 
 
B-Lymphoblastic Leukemia/Lymphoma with dic(9;12)(p13;p13); PAX5/ETV6
 
 
B-Lymphoblastic Leukemia/Lymphoma with ZNF384 Rearrangements
 
 
B-Lymphoblastic Leukemia/Lymphoma with IKZF1 Deletions
 
 
B-Lymphoblastic Leukemia/Lymphoma with TCF3 Rearrangements - Excluding t(1;19) and t(12;19)
 
 
B-Lymphoblastic Leukemia/Lymphoma with dic(9;20)(p13;q11)
|ISSUE- FIX
|ISSUE- FIX


Line 1,664: Line 1,676:
|
|
|-
|-
|[[HAEM5:Monoclonal B-cell lymphocytosis|Monoclonal B-cell lymphocytosis]]||Disease||PENDING; Shashirekha Shetty
!Disease (5th Edition)
!Page Type
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses)
!Date Assigned to Author (5th Edition)
!Target Completion Date (5th Edition)
!Content Status (5th Edition)(Pending or Complete)
!Date Completed by Author (5th Edition)
!Associate Editor
!Date of Last Editor Review (5th Edition)
!Notes (5th Edition)
!Correlated Prior Disease Name (4th Edition)
!Correlated Prior Author (4th Edition)
!Prior Content Status (4th Edition)(Pending or Complete)
!Prior Date of Last Editor Review (4th Edition)
!Prior Notes (4th Edition)
|-
|[[HAEM5:Monoclonal B-cell lymphocytosis|Monoclonal B-cell lymphocytosis]]||Disease||PENDING; Shashirekha Shetty
| ||9/4/2025 sent E-mail reminder|| || ||Shivani Golem (SG)
| ||9/4/2025 sent E-mail reminder|| || ||Shivani Golem (SG)
| ||
| ||
Line 2,348: Line 2,376:
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
!Disease (5th Edition)
!Page Type
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses)
!Date Assigned to Author (5th Edition)
!Target Completion Date (5th Edition)
!Content Status (5th Edition)(Pending or Complete)
!Date Completed by Author (5th Edition)
!Associate Editor
!Date of Last Editor Review (5th Edition)
!Notes (5th Edition)
!Correlated Prior Disease Name (4th Edition)
!Correlated Prior Author (4th Edition)
!Prior Content Status (4th Edition)(Pending or Complete)
!Prior Date of Last Editor Review (4th Edition)
!Prior Notes (4th Edition)
|-
|-
|[[HAEM5:Plasma cell myeloma / multiple myeloma|Plasma cell myeloma / multiple myeloma]]||Disease||Huan Mo;
|[[HAEM5:Plasma cell myeloma / multiple myeloma|Plasma cell myeloma / multiple myeloma]]||Disease||Huan Mo;
Line 2,404: Line 2,416:
|Prior Notes (4th Edition)
|Prior Notes (4th Edition)
|-
|-
|
!Disease (5th Edition)
====CHAPTER 5 (T-CELL AND NK-CELL LYMPHOID PROLIFERATIONS AND LYMPHOMAS)====
!Page Type
|
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses)
----<br />
!Date Assigned to Author (5th Edition)
|
!Target Completion Date (5th Edition)
----<br />
!Content Status (5th Edition)(Pending or Complete)
|
!Date Completed by Author (5th Edition)
----<br />
!Associate Editor
|
!Date of Last Editor Review (5th Edition)
----<br />
!Notes (5th Edition)
|
!Correlated Prior Disease Name (4th Edition)
----<br />
!Correlated Prior Author (4th Edition)
|
!Prior Content Status (4th Edition)(Pending or Complete)
----<br />
!Prior Date of Last Editor Review (4th Edition)
|
!Prior Notes (4th Edition)
----<br />
|-
|
| colspan="15" |
----<br />
====CHAPTER 5 (T-CELL AND NK-CELL LYMPHOID PROLIFERATIONS AND LYMPHOMAS)====
|
|-
----<br />
|[[HAEM5:Kikuchi-Fujimoto disease|Kikuchi-Fujimoto disease]]||Disease|| Sumire Kitahara, MD|| || || '''Complete'''|| 11/6/2025||Sumi Kitahara (SK)
|
| ||
----<br />
|NEW (No Prior)
|
----<br />
|
----<br />
|
----<br />
|
----<br />
|-
|[[HAEM5:Kikuchi-Fujimoto disease|Kikuchi-Fujimoto disease]]||Disease|| || || || || ||Sumi Kitahara (SK)
| ||
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
Line 2,446: Line 2,446:
Karin Miller, MD
Karin Miller, MD
|3/25/2024
|3/25/2024
| || || ||SK|| ||
| ||Pending
| ||SK|| ||
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
Line 2,472: Line 2,473:
|
|
|
|
|Pending
|
|
|
|SK
|SK
Line 2,485: Line 2,486:
|[[HAEM5:T-prolymphocytic leukaemia|T-prolymphocytic leukaemia]]
|[[HAEM5:T-prolymphocytic leukaemia|T-prolymphocytic leukaemia]]
|Disease
|Disease
|Parastou Tizro, MD (trainee);
|Parastou Tizro, MD;
Celeste Eno, PhD
Celeste Eno, PhD; Sumire Kitahara, MD
|3/17/2024
|9/23/2025
|
|11/4/2025
|Complete
|'''Complete'''
|6/24/2024
|11/4/2025
|SK
|SK
|7/1/2024
|11/6/2025
|
|
|NEW (No Prior)
|NEW (No Prior)
Line 2,500: Line 2,501:
|NEW (No Prior)
|NEW (No Prior)
|-
|-
!Disease (5th Edition)
|[[HAEM5:T-large granular lymphocytic leukaemia|T-large granular lymphocytic leukaemia]]||Disease||Nicolas LaScala (trainee);
!Page Type
Michelle Don, MD, MS
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses)
|9/24/2025
!Date Assigned to Author (5th Edition)
|12/9/2025
!Target Completion Date (5th Edition)
|Pending
!Content Status (5th Edition)(Pending or Complete)
| ||SK|| ||
!Date Completed by Author (5th Edition)
|T-cell Large Granular Lymphocytic Leukemia
!Associate Editor
|Michelle Don, MD, MS
!Date of Last Editor Review (5th Edition)
|Pending
!Notes (5th Edition)
|
!Correlated Prior Disease Name (4th Edition)
!Correlated Prior Author (4th Edition)
!Prior Content Status (4th Edition)(Pending or Complete)
!Prior Date of Last Editor Review (4th Edition)
!Prior Notes (4th Edition)
|-
|[[HAEM5:T-large granular lymphocytic leukaemia|T-large granular lymphocytic leukaemia]]||Disease||Nicolas LaScala (trainee);
Michelle Don, MD, MS
|3/17/2024 (trainee name added on 9/9/24 by JH)
|6/30/24
|Pending
| ||SK|| ||
|T-cell Large Granular Lymphocytic Leukemia
|Michelle Don, MD, MS
|Pending
|
|
|
|-
|-
|[[HAEM5:NK-large granular lymphocytic leukaemia|NK-large granular lymphocytic leukaemia]]||Disease||Hailee St. Louis (trainee);  
|[[HAEM5:NK-large granular lymphocytic leukaemia|NK-large granular lymphocytic leukaemia]]||Disease||Hailee St. Louis (trainee);  
Michelle Don, MD, MS
Michelle Don, MD, MS
|3/17/2024
|9/24/2025
|6/30/24
|12/9/2025
|Pending
|'''Complete'''
| ||SK|| ||
| 12/17/2025||SK|| 1/6/2026||
|Chronic Lymphoproliferative Disorder of NK Cells
|Chronic Lymphoproliferative Disorder of NK Cells
|Michelle Don, MD
|Michelle Don, MD
Line 2,553: Line 2,538:
|[[HAEM5:Sezary syndrome|Sezary syndrome]]||Disease||Daynna J. Wolff, PhD
|[[HAEM5:Sezary syndrome|Sezary syndrome]]||Disease||Daynna J. Wolff, PhD
|3/22/2024
|3/22/2024
| || || ||SK|| ||
|follow-up needed
| || ||SK|| ||
|Sézary Syndrome
|Sézary Syndrome
|Madison E. Hannay, DO, Medical University of South Carolina  Tingting Barrett, MD, Medical University of South Carolina  Daynna J. Wolff, PhD, Medical University of South Carolina
|Madison E. Hannay, DO, Medical University of South Carolina  Tingting Barrett, MD, Medical University of South Carolina  Daynna J. Wolff, PhD, Medical University of South Carolina
Line 2,560: Line 2,546:
|
|
|-
|-
|[[HAEM5:Aggressive NK-cell leukaemia|Aggressive NK-cell leukaemia]]||Disease||Rabail Aslam, MD (fellow);
|[[HAEM5:Aggressive NK-cell leukaemia|Aggressive NK-cell leukaemia]]||Disease||Shashirekha Shetty, PhD
Shashirekha Shetty, PhD
|10/15/2025||1/19/2026
|7/1/2024||8/31/2024
|Pending
|Pending
| ||SK|| ||
| ||SK|| ||
Line 2,571: Line 2,556:
|
|
|-
|-
|[[HAEM5:Primary cutaneous CD4-positive small or medium T-cell lymphoproliferative disorder|Primary cutaneous CD4-positive small or medium T-cell lymphoproliferative disorder]]||Disease||Amanda Xu, MD/MSc; Teodora Popa (resident)
!Disease (5th Edition)
|3/19/2024
!Page Type
| ||Pending
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses)
| ||SK|| ||
!Date Assigned to Author (5th Edition)
|NEW (No Prior)
!Target Completion Date (5th Edition)
|NEW (No Prior)
!Content Status (5th Edition)(Pending or Complete)
|NEW (No Prior)
!Date Completed by Author (5th Edition)
|NEW (No Prior)
!Associate Editor
|NEW (No Prior)
!Date of Last Editor Review (5th Edition)
|-
!Notes (5th Edition)
!Correlated Prior Disease Name (4th Edition)
!Correlated Prior Author (4th Edition)
!Prior Content Status (4th Edition)(Pending or Complete)
!Prior Date of Last Editor Review (4th Edition)
!Prior Notes (4th Edition)
|-
|[[HAEM5:Primary cutaneous CD4-positive small or medium T-cell lymphoproliferative disorder|Primary cutaneous CD4-positive small or medium T-cell lymphoproliferative disorder]]||Disease||Ian King, PhD
|1/6/2026
| 2/3/2026||
| ||SK|| ||
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|[[HAEM5:Primary cutaneous acral CD8-positive T-cell lymphoproliferative disorder|Primary cutaneous acral CD8-positive T-cell lymphoproliferative disorder]]||Disease||Ahmed Eladely (trainee);
|[[HAEM5:Primary cutaneous acral CD8-positive T-cell lymphoproliferative disorder|Primary cutaneous acral CD8-positive T-cell lymphoproliferative disorder]]||Disease||Ahmed Eladely (trainee);


Andrew Siref, MD
Andrew Siref, MD
|4/12/2024
|10/14/2025
| ||Pending
|11/24/2025
| ||SK|| ||
|'''Complete'''
| 12/29/2025||SK|| 1/6/2026||
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
Line 2,595: Line 2,597:
|[[HAEM5:Mycosis fungoides|Mycosis fungoides]]||Disease||Daynna J. Wolff, PhD
|[[HAEM5:Mycosis fungoides|Mycosis fungoides]]||Disease||Daynna J. Wolff, PhD
|3/22/2024
|3/22/2024
| || || ||SK|| ||
|follow-up needed|| || ||SK|| ||
|Mycosis Fungoides
|Mycosis Fungoides
|Jane Scribner, MD and Daynna J. Wolff, PhD
|Jane Scribner, MD and Daynna J. Wolff, PhD
Line 2,605: Line 2,607:
Shashirekha Shetty, PhD
Shashirekha Shetty, PhD
|7/1/2024
|7/1/2024
|8/31/224
|follow-up needed
|Pending
|
| ||SK|| ||
| ||SK|| ||
|NEW (No Prior)
|NEW (No Prior)
Line 2,616: Line 2,618:
|[[HAEM5:Primary cutaneous CD30-positive T-cell lymphoproliferative disorder: Primary cutaneous anaplastic large cell lymphoma|Primary cutaneous CD30-positive T-cell lymphoproliferative disorder: Primary cutaneous anaplastic large cell lymphoma]]||Disease||Rabail Aslam, MD (fellow);
|[[HAEM5:Primary cutaneous CD30-positive T-cell lymphoproliferative disorder: Primary cutaneous anaplastic large cell lymphoma|Primary cutaneous CD30-positive T-cell lymphoproliferative disorder: Primary cutaneous anaplastic large cell lymphoma]]||Disease||Rabail Aslam, MD (fellow);
Shashirekha Shetty, PhD
Shashirekha Shetty, PhD
|7/1/2024||8/31/2024
|7/1/2024||follow-up needed
|Pending
|
| ||SK|| ||
| ||SK|| ||
|Primary Cutaneous Anaplastic Large Cell Lymphoma
|Primary Cutaneous Anaplastic Large Cell Lymphoma
Line 2,625: Line 2,627:
|
|
|-
|-
!Disease (5th Edition)
|[[HAEM5:Subcutaneous panniculitis-like T-cell lymphoma|Subcutaneous panniculitis-like T-cell lymphoma]]||Disease||Ian King, PhD
!Page Type
Katelyn Swanson, DO (trainee)
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses)
|11/19/2025
!Date Assigned to Author (5th Edition)
|12/19/2025
!Target Completion Date (5th Edition)
|'''Complete'''
!Content Status (5th Edition)(Pending or Complete)
| 1/6/2026||SK|| 1/6/2026||
!Date Completed by Author (5th Edition)
|NEW (No Prior)
!Associate Editor
|NEW (No Prior)
!Date of Last Editor Review (5th Edition)
|NEW (No Prior)
!Notes (5th Edition)
|NEW (No Prior)
!Correlated Prior Disease Name (4th Edition)
|NEW (No Prior)
!Correlated Prior Author (4th Edition)
|-
!Prior Content Status (4th Edition)(Pending or Complete)
|[[HAEM5:Primary cutaneous gamma/delta T-cell lymphoma|Primary cutaneous gamma/delta T-cell lymphoma]]||Disease||Mahzad Azimpouran (trainee);
!Prior Date of Last Editor Review (4th Edition)
Sumire Kitahara, MD
!Prior Notes (4th Edition)
|-
|[[HAEM5:Subcutaneous panniculitis-like T-cell lymphoma|Subcutaneous panniculitis-like T-cell lymphoma]]||Disease||Raniah Alamri (Hemepath trainee)
|3/19/2024
| ||Pending
| ||SK|| ||
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|[[HAEM5:Primary cutaneous gamma/delta T-cell lymphoma|Primary cutaneous gamma/delta T-cell lymphoma]]||Disease||Mahzad Azimpouran (trainee);
Sumire Kitahara, MD
|6/30/2024
|6/30/2024
| ||Pending
|11/9/2025
|Pending
| ||SK|| ||
| ||SK|| ||
|NEW (No Prior)
|NEW (No Prior)
Line 2,665: Line 2,654:


Andrew Siref, MD
Andrew Siref, MD
|4/12/2024|| ||Pending
|10/14/2025||11/24/2025
| ||SK|| ||
|'''Complete'''
| 12/29/2025||SK|| 1/6/2026||
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
Line 2,680: Line 2,670:
|NEW (No Prior)
|NEW (No Prior)
|-
|-
|[[HAEM5:Indolent T-cell lymphoma of the gastrointestinal tract|Indolent T-cell lymphoma of the gastrointestinal tract]]||Disease||
!Disease (5th Edition)
| || || || ||SK|| ||
!Page Type
|Indolent T-cell Lymphoproliferative Disorder of the Gastrointestinal Tract
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses)
|Derick Okwan-Duodu MD, PhD; Sumire Kitahara, MD
!Date Assigned to Author (5th Edition)
|Pending
!Target Completion Date (5th Edition)
|
!Content Status (5th Edition)(Pending or Complete)
|
!Date Completed by Author (5th Edition)
!Associate Editor
!Date of Last Editor Review (5th Edition)
!Notes (5th Edition)
!Correlated Prior Disease Name (4th Edition)
!Correlated Prior Author (4th Edition)
!Prior Content Status (4th Edition)(Pending or Complete)
!Prior Date of Last Editor Review (4th Edition)
!Prior Notes (4th Edition)
|-
|[[HAEM5:Indolent T-cell lymphoma of the gastrointestinal tract|Indolent T-cell lymphoma of the gastrointestinal tract]]||Disease||
| || || || ||SK|| ||
|Indolent T-cell Lymphoproliferative Disorder of the Gastrointestinal Tract
|Derick Okwan-Duodu MD, PhD; Sumire Kitahara, MD
|Pending
|
|
|-
|-
|[[HAEM5:Indolent NK-cell lymphoproliferative disorder of the gastrointestinal tract|Indolent NK-cell lymphoproliferative disorder of the gastrointestinal tract]]||Disease|| || || || || ||SK|| ||
|[[HAEM5:Indolent NK-cell lymphoproliferative disorder of the gastrointestinal tract|Indolent NK-cell lymphoproliferative disorder of the gastrointestinal tract]]||Disease|| || || || || ||SK|| ||
Line 2,697: Line 2,703:
|[[HAEM5:Enteropathy-associated T-cell lymphoma|Enteropathy-associated T-cell lymphoma]]||Disease||Fnu Monika, MBBS (trainee);  
|[[HAEM5:Enteropathy-associated T-cell lymphoma|Enteropathy-associated T-cell lymphoma]]||Disease||Fnu Monika, MBBS (trainee);  
Andrew Siref, MD
Andrew Siref, MD
|3/20/2024
|10/14/2025
| ||Pending|| ||SK|| ||
| ||Pending|| ||SK|| ||
|Enteropathy-Associated T-cell Lymphoma
|Enteropathy-Associated T-cell Lymphoma
Line 2,707: Line 2,713:
|[[HAEM5:Monomorphic epitheliotropic intestinal T-cell lymphoma|Monomorphic epitheliotropic intestinal T-cell lymphoma]]||Disease||Fnu Monika, MBBS (trainee);  
|[[HAEM5:Monomorphic epitheliotropic intestinal T-cell lymphoma|Monomorphic epitheliotropic intestinal T-cell lymphoma]]||Disease||Fnu Monika, MBBS (trainee);  
Andrew Siref, MD
Andrew Siref, MD
|3/20/2024
|10/14/2025
| ||Pending|| ||SK|| ||
| ||Pending|| ||SK|| ||
|Monomorphic Epitheliotropic Intestinal T-cell Lymphoma
|Monomorphic Epitheliotropic Intestinal T-cell Lymphoma
Line 2,718: Line 2,724:
| || || || ||SK|| ||
| || || || ||SK|| ||
|Intestinal T-cell Lymphoma, Not Otherwise Specified (NOS)
|Intestinal T-cell Lymphoma, Not Otherwise Specified (NOS)
|Derick Okwan MD, PhD (Stanford Medicine, CA)  Sumire Kitahara MD (Cedars-Sinai, CA)
|Derick Okwan MD, PhD (Stanford)  Sumire Kitahara MD (Cedars-Sinai)
|Complete
|Complete
|9/26/2022
|9/26/2022
Line 2,725: Line 2,731:
|[[HAEM5:Hepatosplenic T-cell lymphoma|Hepatosplenic T-cell lymphoma]]||Disease||Forough Sargolzaeiaval (trainee);  
|[[HAEM5:Hepatosplenic T-cell lymphoma|Hepatosplenic T-cell lymphoma]]||Disease||Forough Sargolzaeiaval (trainee);  
Michelle Don, MD, MS
Michelle Don, MD, MS
|3/19/2024
|9/24/2025
|6/30/24
|11/9/2025
|Complete
|'''Complete'''
|5/13/24||SK||10/18/24||
|12/17/2025
|SK||1/6/2026||
|Hepatosplenic T-cell Lymphoma
|Hepatosplenic T-cell Lymphoma
|Michelle Don, MD, MS
|Michelle Don, MD, MS
Line 2,734: Line 2,741:
|1/21/2021
|1/21/2021
|
|
|-
!Disease (5th Edition)
!Page Type
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses)
!Date Assigned to Author (5th Edition)
!Target Completion Date (5th Edition)
!Content Status (5th Edition)(Pending or Complete)
!Date Completed by Author (5th Edition)
!Associate Editor
!Date of Last Editor Review (5th Edition)
!Notes (5th Edition)
!Correlated Prior Disease Name (4th Edition)
!Correlated Prior Author (4th Edition)
!Prior Content Status (4th Edition)(Pending or Complete)
!Prior Date of Last Editor Review (4th Edition)
!Prior Notes (4th Edition)
|-
|-
|[[HAEM5:ALK-positive anaplastic large cell lymphoma|ALK-positive anaplastic large cell lymphoma]]||Disease||Miguel Gonzalez Mancera, MD (trainee);
|[[HAEM5:ALK-positive anaplastic large cell lymphoma|ALK-positive anaplastic large cell lymphoma]]||Disease||Miguel Gonzalez Mancera, MD (trainee);


Sumire Kitahara, MD
Sumire Kitahara, MD
|6/6/24|| ||Pending
|6/6/24|| ||
| ||SK|| ||
| ||SK|| ||
|Anaplastic Large Cell Lymphoma, ALK-Positive
|Anaplastic Large Cell Lymphoma, ALK-Positive
Line 2,768: Line 2,759:
|[[HAEM5:ALK-negative anaplastic large cell lymphoma|ALK-negative anaplastic large cell lymphoma]]||Disease||Miguel Gonzalez Mancera, MD (trainee);
|[[HAEM5:ALK-negative anaplastic large cell lymphoma|ALK-negative anaplastic large cell lymphoma]]||Disease||Miguel Gonzalez Mancera, MD (trainee);
Sumire Kitahara, MD
Sumire Kitahara, MD
|6/6/24|| ||Pending
|6/6/24|| ||
| ||SK|| ||
| ||SK|| ||
|Anaplastic Large Cell Lymphoma, ALK-Negative
|Anaplastic Large Cell Lymphoma, ALK-Negative
Line 2,777: Line 2,768:
|-
|-
|[[HAEM5:Breast implant-associated anaplastic large cell lymphoma|Breast implant-associated anaplastic large cell lymphoma]]||Disease||Lynne Abruzzo, MD, PhD
|[[HAEM5:Breast implant-associated anaplastic large cell lymphoma|Breast implant-associated anaplastic large cell lymphoma]]||Disease||Lynne Abruzzo, MD, PhD
|4/1/2024
|9/22/2025
| ||Pending|| ||SK|| ||
|1/1/2026
|Pending|| ||SK|| ||
|Breast Implant-Associated Anaplastic Large Cell Lymphoma
|Breast Implant-Associated Anaplastic Large Cell Lymphoma
|Derick Okwan-Duodu, MD, PhD; Sumire Kitahara, MD  Cedars-Sinai Medical Center
|Derick Okwan-Duodu, MD, PhD; Sumire Kitahara, MD  Cedars-Sinai Medical Center
Line 2,785: Line 2,777:
|
|
|-
|-
|[[HAEM5:Nodal TFH cell lymphoma, angioimmunoblastic-type|Nodal TFH cell lymphoma, angioimmunoblastic-type]]||Disease||Rachel Burnside, PhD||7/28/2023
!Disease (5th Edition)
| ||Pending|| ||SK|| ||prior authors not available
!Page Type
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses)
!Date Assigned to Author (5th Edition)
!Target Completion Date (5th Edition)
!Content Status (5th Edition)(Pending or Complete)
!Date Completed by Author (5th Edition)
!Associate Editor
!Date of Last Editor Review (5th Edition)
!Notes (5th Edition)
!Correlated Prior Disease Name (4th Edition)
!Correlated Prior Author (4th Edition)
!Prior Content Status (4th Edition)(Pending or Complete)
!Prior Date of Last Editor Review (4th Edition)
!Prior Notes (4th Edition)
|-
|[[HAEM5:Nodal TFH cell lymphoma, angioimmunoblastic-type|Nodal TFH cell lymphoma, angioimmunoblastic-type]]||Disease||Rachel Burnside, PhD||7/28/2023
|follow-up needed
| || ||SK|| ||prior authors not available
|Angioimmunoblastic T-cell Lymphoma
|Angioimmunoblastic T-cell Lymphoma
|Sara Akhavanfard, M.D., Ph.D. and Ruthann Pfau, Ph.D., FACMG
|Sara Akhavanfard, M.D., Ph.D. and Ruthann Pfau, Ph.D., FACMG
Line 2,794: Line 2,803:
|-
|-
|[[HAEM5:Nodal TFH cell lymphoma, follicular-type|Nodal TFH cell lymphoma, follicular-type]]||Disease||Rachel Burnside, PhD||7/28/2023
|[[HAEM5:Nodal TFH cell lymphoma, follicular-type|Nodal TFH cell lymphoma, follicular-type]]||Disease||Rachel Burnside, PhD||7/28/2023
| ||Pending|| ||SK|| ||
|follow-up needed
| || ||SK|| ||
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
Line 2,810: Line 2,820:
|-
|-
|[[HAEM5:Peripheral T-cell lymphoma, NOS|Peripheral T-cell lymphoma, NOS]]||Disease||Bo Hong, MD
|[[HAEM5:Peripheral T-cell lymphoma, NOS|Peripheral T-cell lymphoma, NOS]]||Disease||Bo Hong, MD
|6/25/2023
|10/14/2025
| || || ||SK|| ||
|12/3/2025
|Pending
| ||SK|| ||
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
Line 2,820: Line 2,832:
|[[HAEM5:EBV-positive nodal T- and NK-cell lymphoma|EBV-positive nodal T- and NK-cell lymphoma]]||Disease||Fnu Monika, MBBS (trainee);
|[[HAEM5:EBV-positive nodal T- and NK-cell lymphoma|EBV-positive nodal T- and NK-cell lymphoma]]||Disease||Fnu Monika, MBBS (trainee);
Andrew Siref, MD
Andrew Siref, MD
|3/22/2024|| ||Pending|| ||SK|| ||
|10/14/2025|| ||Pending|| ||SK|| ||
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
Line 2,827: Line 2,839:
|NEW (No Prior)
|NEW (No Prior)
|-
|-
|[[HAEM5:Extranodal NK/T-cell lymphoma|Extranodal NK/T-cell lymphoma]]||Disease||Amanda Xu, MD/MSc;
|[[HAEM5:Extranodal NK/T-cell lymphoma|Extranodal NK/T-cell lymphoma]]||Disease||Maryam Mehdiopour Dalivand (trainee); Ian King, PhD
Teodora Popa (resident)
|1/6/2026
|3/19/2024
| 2/3/2026||Pending
| ||Pending
| ||SK|| ||
| ||SK|| ||
|NEW (No Prior)
|NEW (No Prior)
Line 2,844: Line 2,855:
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
!Disease (5th Edition)
!Page Type
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses)
!Date Assigned to Author (5th Edition)
!Target Completion Date (5th Edition)
!Content Status (5th Edition)(Pending or Complete)
!Date Completed by Author (5th Edition)
!Associate Editor
!Date of Last Editor Review (5th Edition)
!Notes (5th Edition)
!Correlated Prior Disease Name (4th Edition)
!Correlated Prior Author (4th Edition)
!Prior Content Status (4th Edition)(Pending or Complete)
!Prior Date of Last Editor Review (4th Edition)
!Prior Notes (4th Edition)
|-
|-
|[[HAEM5:Hydroa vacciniforme lymphoproliferative disorder|Hydroa vacciniforme lymphoproliferative disorder]]||Disease|| || || || || ||SK|| ||
|[[HAEM5:Hydroa vacciniforme lymphoproliferative disorder|Hydroa vacciniforme lymphoproliferative disorder]]||Disease|| || || || || ||SK|| ||
Line 2,870: Line 2,865:
|[[HAEM5:Systemic chronic active EBV disease|Systemic chronic active EBV disease]]||Disease||Karin Miller, MD
|[[HAEM5:Systemic chronic active EBV disease|Systemic chronic active EBV disease]]||Disease||Karin Miller, MD
|3/25/2024
|3/25/2024
| || || ||SK|| ||
| 11/17/2025||Pending
| ||SK|| ||
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
Line 2,879: Line 2,875:
|[[HAEM5:Systemic EBV-positive T-cell lymphoma of childhood|Systemic EBV-positive T-cell lymphoma of childhood]]||Disease||Karin Miller, MD
|[[HAEM5:Systemic EBV-positive T-cell lymphoma of childhood|Systemic EBV-positive T-cell lymphoma of childhood]]||Disease||Karin Miller, MD
|3/25/2024
|3/25/2024
| || || ||SK|| ||prior authors not available
| 11/17/2025||Pending
| ||SK|| ||prior authors not available
|Systemic EBV-Positive T-cell Lymphoma of Childhood
|Systemic EBV-Positive T-cell Lymphoma of Childhood
|Lisa A. Lansdon, PhD and Linda D. Cooley, MD, MBA
|Lisa A. Lansdon, PhD and Linda D. Cooley, MD, MBA
Line 2,885: Line 2,882:
|11/21/2021
|11/21/2021
|
|
|-
!Disease (5th Edition)
!Page Type
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses)
!Date Assigned to Author (5th Edition)
!Target Completion Date (5th Edition)
!Content Status (5th Edition)(Pending or Complete)
!Date Completed by Author (5th Edition)
!Associate Editor
!Date of Last Editor Review (5th Edition)
!Notes (5th Edition)
!Correlated Prior Disease Name (4th Edition)
!Correlated Prior Author (4th Edition)
!Prior Content Status (4th Edition)(Pending or Complete)
!Prior Date of Last Editor Review (4th Edition)
!Prior Notes (4th Edition)
|-
|-
|
|
Line 2,980: Line 2,993:
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
!Disease (5th Edition)
!Page Type
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses)
!Date Assigned to Author (5th Edition)
!Target Completion Date (5th Edition)
!Content Status (5th Edition)(Pending or Complete)
!Date Completed by Author (5th Edition)
!Associate Editor
!Date of Last Editor Review (5th Edition)
!Notes (5th Edition)
!Correlated Prior Disease Name (4th Edition)
!Correlated Prior Author (4th Edition)
!Prior Content Status (4th Edition)(Pending or Complete)
!Prior Date of Last Editor Review (4th Edition)
!Prior Notes (4th Edition)
|-
|-
|[[HAEM5:Littoral cell angioma|Littoral cell angioma]]
|[[HAEM5:Littoral cell angioma|Littoral cell angioma]]
Line 3,044: Line 3,041:
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
!Disease (5th Edition)
!Page Type
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses)
!Date Assigned to Author (5th Edition)
!Target Completion Date (5th Edition)
!Content Status (5th Edition)(Pending or Complete)
!Date Completed by Author (5th Edition)
!Associate Editor
!Date of Last Editor Review (5th Edition)
!Notes (5th Edition)
!Correlated Prior Disease Name (4th Edition)
!Correlated Prior Author (4th Edition)
!Prior Content Status (4th Edition)(Pending or Complete)
!Prior Date of Last Editor Review (4th Edition)
!Prior Notes (4th Edition)
|-
|-
|
|
Retrieved from "https://test.ccga.io/index.php/HAEM5:Volunteer_Assignments_and_Opportunities"